Pharmacokinetics of Astromicin Following a Single Intravenous Infusion in Healthy Korean Subjects

정상성인 한국인에서 아스트로마이신 1회 점적 주사후 약물동태학적 평가

  • Bok, Hae Sook (Clinical Trial Center, Samsung Biomedical Research Institute, Division of Pharmaceutical Services) ;
  • Choi, Kyung Eob (Samsung Medical Center) ;
  • Kim, Yeon Hwa (Samsung Medical Center) ;
  • Peck, Kyong Ran (Samsung Medical Center, Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University) ;
  • Song, Jae Hoon (Samsung Medical Center, Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University)
  • Published : 2003.12.01

Abstract

Astromicin is an aminoglycoside antiviotic that is structually different from conventional aminoglycosides. Astromicin has been shown to be active against aerobic Gram-negative bacilli. The pharmacokinetics of astromicin were determined in 12 healthy volunteers ($65.5\pm5.23\;kg$ of body weight) following a 30-min continuous intravenous infusion at a dose of 200 mg. The plasma and urine samples were collected up to 24 h and drug concentrations were measured by a bioassay using Bacillus subtilis. Pharmacokinetic parameters were calculated by fitting individual concentration-time curve to a one-exponential decay model. The plasma levels were $16.9\pm1.68\;and\;1.05\pm0.346\l{\mu}g/ml$ at 0 h and 8 h after the infusion, respectively. The elimination half-life of astromicin was $1.86\pm0.360\;h$ The volume of distribution was $0.182\pm0.0164\;L/kg$, and the total body clearance was $5.25\pm1.74\;L/h$. These pharmacokinetic parameters were similar to these of gentamicin, tobramycin, and amikacin. Therefore, it is recommended that therapeutic drug monitoring of astromicin could be conducted in a similar fashion as the other aminoglycosides.

Keywords